Stryker (SYK) Expected to Announce Earnings on Thursday

Stryker (NYSE:SYK) is expected to announce its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect the company to post earnings of $3.55 per share and revenue of $6.62 billion for the quarter. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Interested persons may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%. The company had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. During the same quarter last year, the firm posted $3.13 earnings per share. Stryker’s revenue was up 9.4% compared to the same quarter last year. On average, analysts expect Stryker to post $14.93 EPS for the current fiscal year and $16.60 EPS for the next fiscal year.

Stryker Stock Performance

Shares of SYK opened at $297.30 on Thursday. The firm has a market cap of $114.03 billion, a P/E ratio of 30.81, a PEG ratio of 1.96 and a beta of 0.78. Stryker has a twelve month low of $267.00 and a twelve month high of $392.55. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The firm’s 50 day moving average price is $296.53 and its two-hundred day moving average price is $312.13.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Insider Transactions at Stryker

In related news, Director Ronda Stryker sold 50,000 shares of Stryker stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the sale, the director directly owned 2,251,375 shares in the company, valued at $765,692,637.50. This trade represents a 2.17% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Debra King sold 826 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the transaction, the insider directly owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This represents a 11.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 351,267 shares of company stock worth $118,197,701. Insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

SYK has been the subject of several recent research reports. Wells Fargo & Company reduced their target price on shares of Stryker from $418.00 to $348.00 and set an “overweight” rating for the company in a report on Wednesday, September 9th. Sanford C. Bernstein reissued a “market perform” rating on shares of Stryker in a research note on Wednesday, October 7th. Evercore set a $350.00 target price on shares of Stryker in a research note on Monday, July 6th. Piper Sandler dropped their price target on Stryker from $420.00 to $390.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. Finally, Barclays upgraded shares of Stryker to a “strong-buy” rating in a research note on Wednesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $369.00.

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.